|
|
|
|
LEADER |
01909nam a2200289 u 4500 |
001 |
EB002001102 |
003 |
EBX01000000000000001164003 |
005 |
00000000000000.0 |
007 |
tu||||||||||||||||||||| |
008 |
210907 r ||| eng |
245 |
0 |
0 |
|a High-dose stimulants for attention-deficit/hyperactivity disorder
|h Elektronische Ressource
|b a review of the clinical effectiveness, safety and guidelines
|c prepared by Canadian Agency for Drugs and Technologies in Health
|
260 |
|
|
|a [Ottawa]
|b Canadian Agency for Drugs and Technologies in Health
|c 2016, 3 March 2016
|
300 |
|
|
|a 1 PDF file (24 pages)
|
505 |
0 |
|
|a Includes bibliographical references
|
653 |
|
|
|a Attention Deficit Disorder with Hyperactivity / drug therapy
|
653 |
|
|
|a Comparative Effectiveness Research
|
653 |
|
|
|a Central Nervous System Stimulants / administration & dosage
|
653 |
|
|
|a Treatment Outcome
|
653 |
|
|
|a Practice Guidelines as Topic
|
653 |
|
|
|a Central Nervous System Stimulants / therapeutic use
|
710 |
2 |
|
|a Canadian Agency for Drugs and Technologies in Health
|
041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
989 |
|
|
|b NCBI
|a National Center for Biotechnology Information
|
490 |
0 |
|
|a Rapid response report
|
856 |
4 |
0 |
|u https://www.ncbi.nlm.nih.gov/books/NBK355613
|3 Volltext
|n NLM Bookshelf Books
|3 Volltext
|
082 |
0 |
|
|a 610
|
520 |
|
|
|a This review considers the use of short, intermediate, and/or long acting stimulants, such as, methylphenidate, amphetamine, dextro-amphetamine, and lisdexamfetamine, in children and adults. Many persons with attention-deficit/hyperactivity disorder (ADHD) require individualized, optimal dose-titration to address symptoms, and it is recommended that patients start on the lowest possible dose and titrate upwards to appropriately manage symptoms. This review aims to address concerns regarding the effectiveness and safety of the use of stimulants at higher than recommended doses
|